Aerie Pharmaceuticals Inc. (AERI) Is Surging On Phase 3 Study Results
- Author: Zachary Reyes Sep 17, 2016,
Sep 17, 2016, 11:18
Aerie Pharmaceuticals Inc are listed in the Health Care sector within NASDAQ.
In addition to the US$50mln raised separately through an "at the market program" via broker Cantor Fitzgerald, the group raised a total of US$125mln.
AERI has been the subject of a number of other reports.
Out of 7 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 7 rate it a "Buy", 0 "Sell", while 0 "Hold". They now have a United States dollars 50 price target on the stock. Raymond James Financial Inc. assumed coverage on Aerie Pharmaceuticals in a research report on Tuesday. They issued a "buy" rating and a $44.00 price target for the company. Separately, on the same day, Brean Capital's Difei Yang reiterated a Buy rating on the stock and has a price target of $48. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Current stock price is in the upbeat territory taking into account of 20 days moving average with 68.73% and continued bullish run for 50 days moving average with 78.46%. AERI Director Mehra Anand also sold 425,000 shares, at a stock price of $33.64. Market capitalisation for NASDAQ:AERI is $803,123,340.00 United States dollars.
As for as concerns shares volumes, in share of capital Immune Pharmaceuticals, Inc.
AERIE PHARMACEUTICALS, INC. (AERI) received consensus recommendation of "Buy" from Analysts polled at Thomson Reuters.
Earnings Roundup: In the last fiscal quarter alone, Aerie Pharmaceuticals, Inc. generated almost $0 in sales and net income of -$7.20E-01/share.
Aerie Pharmaceuticals is now covered by 6 Wall Street analysts.
Several other biotech stocks rallied Wednesday.
"Year Ending Dec-17" Analyst are expecting that the company to declare next quarterly earnings of $6 per share for period -2.57. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 9 funds bought stakes while 46 increased positions.
Aerie Pharmaceuticals Inc said on Wednesday its eye drug met the main goal in a late stage study, sending its shares up 71 percent in extended trading. BlackRock Institutional Trust Company N.A. now owns 652,151 shares of the company's stock valued at $7,930,000 after buying an additional 65,298 shares in the last quarter. Dafna Capital Management Llc owns 160,869 shares or 2.24% of their United States portfolio.
The company submitted a marketing application for Rhopressa - a once-daily eye drop to treat patients with glaucoma or ocular hypertension - to the U.S. Food and Drug Administration last week. Nonetheless, the Roclatan results provided Aerie with an opportunity to top up its cash pile: the company did not permit even a single trading session to pass before announcing a $50m fund raising.